Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
W Gao, X Wang, Y Zhou, X Wang, Y Yu - Signal transduction and …, 2022 - nature.com
In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …
TIMER2. 0 for analysis of tumor-infiltrating immune cells
Tumor progression and the efficacy of immunotherapy are strongly influenced by the
composition and abundance of immune cells in the tumor microenvironment. Due to the …
composition and abundance of immune cells in the tumor microenvironment. Due to the …
Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO …
S Fukuoka, H Hara, N Takahashi, T Kojima… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal
cancer. PATIENTS AND METHODS Enrolled patients received regorafenib plus nivolumab …
cancer. PATIENTS AND METHODS Enrolled patients received regorafenib plus nivolumab …
Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response
Background Although immune checkpoint inhibitor (ICI) is regarded as a breakthrough in
cancer therapy, only a limited fraction of patients benefit from it. Cancer stemness can be the …
cancer therapy, only a limited fraction of patients benefit from it. Cancer stemness can be the …
Enhancing anti-tumour efficacy with immunotherapy combinations
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
[HTML][HTML] Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors
V Leko, SA Rosenberg - Cancer Cell, 2020 - cell.com
Cancer elimination in humans can be achieved with immunotherapy that relies on T
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical
benefits, but only a fraction of patients respond to treatment. To predict ICB response, we …
benefits, but only a fraction of patients respond to treatment. To predict ICB response, we …
The hallmarks of successful anticancer immunotherapy
Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only
a fraction of patients with cancer responds to immunotherapy, and currently available …
a fraction of patients with cancer responds to immunotherapy, and currently available …
Genomic correlates of response to immune checkpoint blockade
TE Keenan, KP Burke, EM Van Allen - Nature medicine, 2019 - nature.com
Despite impressive durable responses, immune checkpoint inhibitors do not provide a long-
term benefit to the majority of patients with cancer. Understanding genomic correlates of …
term benefit to the majority of patients with cancer. Understanding genomic correlates of …